Disease Overview
Why Type 2 Diabetes Demands Specialized BRA
The T2D landscape has been transformed by GLP-1 receptor agonists and SGLT2 inhibitors delivering cardiovascular and renal benefits beyond glycemic control. This expansion of indications—from diabetes to obesity, heart failure, and CKD—creates overlapping safety populations and complex benefit-risk profiles that require disease-specific analytical frameworks.
GLP-1 Thyroid & Pancreatitis Risk
Semaglutide, tirzepatide, and liraglutide carry FDA boxed warnings for thyroid C-cell tumor risk based on rodent studies, alongside signals for acute pancreatitis. As these agents expand into obesity and cardiovascular indications, BRA must model class-wide thyroid safety across broader populations with longer exposure durations than original diabetes CVOTs.
SGLT2 DKA & Genitourinary Safety
Empagliflozin, dapagliflozin, and canagliflozin present a unique safety constellation including euglycemic diabetic ketoacidosis, Fournier's gangrene, lower limb amputations (canagliflozin), and urinary tract infections. Cross-indication use in heart failure and CKD patients without diabetes introduces novel risk-benefit considerations.
Cardiovascular Outcome Trial Requirements
Since the 2008 FDA CVOT guidance, every new T2D therapy must demonstrate cardiovascular safety. This has generated massive datasets from EMPA-REG OUTCOME, DECLARE-TIMI 58, SUSTAIN-6, PIONEER 6, and SURPASS trials that require integrated benefit-risk modeling across MACE endpoints, hospitalization for heart failure, and renal composite outcomes.
Platform Capabilities
How ArcaScience Addresses Type 2 Diabetes BRA
Our platform integrates T2D-specific CVOT data, class-level safety models for GLP-1 and SGLT2 agents, and regulatory templates aligned with FDA cardiovascular guidance, EMA benefit-risk methodology, and PMDA requirements for metabolic therapies.
T2D Data Coverage
8,500+ T2D clinical trials including EMPA-REG OUTCOME, DECLARE-TIMI 58, SUSTAIN, PIONEER, SURPASS, and AMPLITUDE-O datasets. Adverse event data covering GLP-1 thyroid signals, SGLT2 DKA and genitourinary events, insulin hypoglycemia patterns, and cardiovascular outcome endpoints across all major drug classes.
Explore Data Engine →CVOT-Integrated AI Models
AI models for cardiovascular outcome modeling across MACE, HHF, and renal composites, GLP-1 thyroid C-cell risk extrapolation from preclinical to clinical data, SGLT2 DKA risk stratification in diabetic and non-diabetic populations, and cross-indication safety modeling for obesity and heart failure expansions.
Explore AI Models →T2D Regulatory Outputs
PSURs with cardiovascular safety deep-dives for GLP-1 and SGLT2 agents, RMPs with DKA monitoring and thyroid risk minimization measures, CTD Module 2.5 with CVOT endpoint integration, and HEOR reports supporting NICE and G-BA submissions for cardiovascular and renal benefit claims.
Explore Outputs →Type 2 Diabetes Intelligence
Platform Performance in T2D
T2D adverse event data points
Faster CVOT safety signal integration
Drug classes modeled end-to-end
T2D regulatory submissions supported
Case Evidence — Type 2 Diabetes
Post-Marketing Cardiovascular Safety Signal Monitoring for GLP-1 Agonists
Challenge
A top-10 pharma company needed real-time cardiovascular safety signal monitoring for their GLP-1 receptor agonist as it expanded from T2D into obesity and cardiovascular risk reduction indications, requiring integrated BRA across three distinct patient populations with differing baseline cardiovascular risk profiles.
Result
ArcaScience deployed cross-indication cardiovascular safety models integrating CVOT data, real-world evidence from claims databases, and spontaneous reporting systems. The platform detected a potential pancreatitis signal enrichment in the obesity population 4.1 months earlier than traditional pharmacovigilance methods, enabling proactive label update discussions with FDA and EMA.
Earlier signal detection vs. traditional PV
Reduction in CVOT data integration time
VP, Global Pharmacovigilance
Top-10 Pharmaceutical Company
Frequently Asked Questions